Status:
COMPLETED
Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Resectable Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Pancreatic cancer represents the fourth cause of death by cancer in western countries. The only curative treatment is surgery but this one is possible only in 10 to 15 % of cases. To date, there are f...
Detailed Description
The investigators will analyze if the tumor mobilization increases circulating DNA rate in peripheral and portal blood. Moreover, circulating tumor DNA will be measured during 12 months after surgery ...
Eligibility Criteria
Inclusion
- Every patient taken care by Toulouse University Hospital for the resection of a non-metastatic pancreatic adenocarcinoma by whipple resection.
- Patient aged over 18 years old
- Patient having given his written consent
- Patient with social insurance coverage
Exclusion
- Patients who had surgery, but their pathological examination of the resected specimen does not contain adenocarcinoma.
- Patient for whom the surgery was not realized (exploratory laparotomy)
Key Trial Info
Start Date :
February 26 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 20 2022
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT03435536
Start Date
February 26 2018
End Date
June 20 2022
Last Update
November 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Toulouse, France, 31059